Evolocumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09303 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | symptomatic form of hemophilia in female carriers | KG + DL |
| 2 | familial apolipoprotein C-II deficiency | KG + DL |
| 3 | thrombocytopenic purpura | KG + DL |
| 4 | factor XI deficiency | KG + DL |
| 5 | hemophilia A with vascular abnormality | KG + DL |
| 6 | disease of catalytic activity | KG + DL |
| 7 | hemorrhagic disease of newborn | KG + DL |
| 8 | ichthyosis, X-linked, without steroid sulfatase deficiency | KG + DL |
| 9 | inherited thrombophilia | KG + DL |
| 10 | disorder of other vitamins and cofactors metabolism and transport | KG + DL |
| 11 | adenosine deaminase deficiency | KG + DL |
| 12 | xanthomatosis (disease) | KG + DL |
| 13 | esophageal varices with bleeding | KG + DL |
| 14 | esophageal varices without bleeding | KG + DL |
| 15 | 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect | KG + DL |
| 16 | 3-hydroxyacyl-CoA dehydrogenase deficiency | KG + DL |
| 17 | cholesterol catabolic process disease | KG + DL |
| 18 | coagulation protein disease | KG + DL |
| 19 | 46,XY disorder of sex development due to a cholesterol synthesis defect | KG + DL |
| 20 | neutral lipid storage disease | KG + DL |
| 21 | dappled diaphyseal dysplasia | KG + DL |
| 22 | thrombotic thrombocytopenic purpura | KG + DL |
| 23 | varicose disease | KG + DL |
| 24 | spastic paraplegia-optic atrophy-neuropathy and spastic paraplegia-optic atrophy-neuropathy-related disorder | KG + DL |
| 25 | Astley-Kendall dysplasia | KG + DL |
| 26 | chondrodysplasia punctata, tibial-metacarpal type | KG + DL |
| 27 | acquired coagulation factor deficiency | KG + DL |
| 28 | hemophilia | KG + DL |
| 29 | chondrodysplasia punctata, brachytelephalangic, autosomal | KG + DL |
| 30 | lipase deficiency, combined | KG + DL |
| 31 | glaucoma | KG + DL |
| 32 | Glanzmann thrombasthenia | KG + DL |
| 33 | reticular dysgenesis | KG + DL |
| 34 | spastic paraplegia | KG + DL |
| 35 | primary release disorder of platelets | KG + DL |
| 36 | severe combined immunodeficiency due to LCK deficiency | KG + DL |
| 37 | Scott syndrome | KG + DL |
| 38 | non-syndromic esophageal malformation | KG + DL |
| 39 | pseudo-von Willebrand disease | KG + DL |
| 40 | congenital factor V deficiency | KG + DL |
| 41 | disorder of phospholipids, sphingolipids and fatty acids biosynthesis | KG + DL |
| 42 | flood factor deficiency | KG + DL |
| 43 | biotin metabolic disease | KG + DL |
| 44 | hypophosphatasia | KG + DL |
| 45 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 46 | acquired hemophilia | KG + DL |
| 47 | hemorrhagic disorder due to a platelet anomaly | KG + DL |
| 48 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 49 | hereditary thrombocytosis with transverse limb defect | KG + DL |
| 50 | familial thrombomodulin anomalies | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.